ISAL 2023 | Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the key differences between the International Consensus Classification (ICC) and World Health Organization (WHO) classification systems from the perspective of acute myeloid leukemia (AML), and explains the main updates in the 2022 European LeukemiaNet (ELN) risk classification. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK, Hermavant, AvenCell, Cellularity, CTI Pharma, Kura Onc, Rigel: Advisory board
Takeda, Aptevo, Epizyme. Syntrix: DSMB
AbbVie: Steering committee
BerGenBio: Focus group
Jazz: Grand rounds
